Evaluation of Copovithane as a Nonspecific Immunomodulator in Surgically Simulated Sepsis
Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis. The purpose of this study was to compare CPV with muramyl dipeptide (MDP), (in immunomodulator of proven efficacy in simulated surgical infection. Six gr...
Gespeichert in:
| Veröffentlicht in: | Journal of investigative surgery 1989, Vol.2 (4), p.423-429 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 4 |
| container_start_page | 423 |
| container_title | Journal of investigative surgery |
| container_volume | 2 |
| creator | Hershman, Michael J. Trachtenberg, Laura S. Pietsch, James D. Richard Mooney, T. H. Deweese, R. Craig Cheadle, William G. |
| description | Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis. The purpose of this study was to compare CPV with muramyl dipeptide (MDP), (in immunomodulator of proven efficacy in simulated surgical infection. Six groups of CBA/J mice were compared; they received intramuscular injections of normal saline (controls), MDP (100 µg), or CPV (100, 200, and 400 mg/kg) 24 h prior to bacterial challenge. The challenge consisted of a Klebsiella-impregnated thigh suture. The first experiment assessed survival after bacterial challenge. The MDP and the CPV groups both had median survival times of 3 days, significantly longer than the control group (1 day, p |
| doi_str_mv | 10.3109/08941938909018267 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79571464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79571464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-b4e1acf31024cf5ce5b4d725a2a6df77c069f46050899e74996054efabf44bef3</originalsourceid><addsrcrecordid>eNp9UMtKxDAUDaLo-PgAF0JW7qpJmz6CbmQYdWDQxejCVblNEyeSNjVplfl7U2YQRHR1L_c8uOcgdErJRUIJvyQFZ5QnBSec0CLO8h00oWlMI5KmyS6ajHgUCPwAHXr_RgiJGU_20X7MioKQbIJeZh9gBui1bbFVeGo7-6H7FbQSg8eAH2zrOym00gLPm2ZobWPrwUBvHdYtXg7uVQswZo2XuhnvssZL2Xntj9GeAuPlyXYeoefb2dP0Plo83s2nN4tIxFnRRxWTFIQKcWImVCpkWrE6j1OIIatVnguSccUykoYsXOaM87AzqaBSjFVSJUfofOPbOfs-SN-XjfZCGhMy2MGXOU9zyjIWiHRDFM5676QqO6cbcOuSknKss_xVZ9Ccbc2HqpH1t2LbX8CvN7hulXUNfFpn6rKHtbFOOWiF9qP13_ZXP-QrCaZfCXCyfLODa0Nv_zz3BYlAlpY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79571464</pqid></control><display><type>article</type><title>Evaluation of Copovithane as a Nonspecific Immunomodulator in Surgically Simulated Sepsis</title><source>Taylor & Francis:Master (3349 titles)</source><source>MEDLINE</source><creator>Hershman, Michael J. ; Trachtenberg, Laura S. ; Pietsch, James D. ; Richard Mooney, T. H. ; Deweese, R. Craig ; Cheadle, William G.</creator><creatorcontrib>Hershman, Michael J. ; Trachtenberg, Laura S. ; Pietsch, James D. ; Richard Mooney, T. H. ; Deweese, R. Craig ; Cheadle, William G.</creatorcontrib><description>Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis. The purpose of this study was to compare CPV with muramyl dipeptide (MDP), (in immunomodulator of proven efficacy in simulated surgical infection. Six groups of CBA/J mice were compared; they received intramuscular injections of normal saline (controls), MDP (100 µg), or CPV (100, 200, and 400 mg/kg) 24 h prior to bacterial challenge. The challenge consisted of a Klebsiella-impregnated thigh suture. The first experiment assessed survival after bacterial challenge. The MDP and the CPV groups both had median survival times of 3 days, significantly longer than the control group (1 day, p <.05). In the second experiment, animals were sacrificed at 6, 24, and 48 h following bacterial challenge, and blood and infected muscle were taken for quantitative bacteriology. At 6 h, there was no difference between groups. Both the MDP rind CPV groups had significantly (p <. 05) lower blood bacterial counts than the control group at 24 and 48 h. Both the MDP and CVP groups had significantly lower local bacterial recovery than controls at 48 h (p <. 05), and local bacterial recovery of the MDP group was significantly lower than the control group at 24 h (p <.05). CPV improved survival and reduced local and systemic bacterial recovery compared with controls. Although the effect of CPV was similar to MDP in this model, it consistently was of lower magnitude and had a narrow dose range.</description><identifier>ISSN: 0894-1939</identifier><identifier>EISSN: 1521-0553</identifier><identifier>DOI: 10.3109/08941938909018267</identifier><identifier>PMID: 2488006</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Acetylmuramyl-Alanyl-Isoglutamine - therapeutic use ; Adjuvants, Immunologic - therapeutic use ; Animals ; Carbamates - therapeutic use ; Copovithane ; Disease Models, Animal ; Equipment Contamination ; immunomodulator ; infection ; Klebsiella Infections - etiology ; Klebsiella Infections - immunology ; Klebsiella Infections - therapy ; Klebsiella pneumoniae - immunology ; Mice ; Mice, Inbred CBA ; muramyl dipeptide ; Povidone - therapeutic use ; Sepsis - etiology ; Sepsis - immunology ; Sepsis - therapy ; Surgical Wound Infection - etiology ; Surgical Wound Infection - immunology ; Surgical Wound Infection - therapy ; Sutures</subject><ispartof>Journal of investigative surgery, 1989, Vol.2 (4), p.423-429</ispartof><rights>1989 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1989</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c268t-b4e1acf31024cf5ce5b4d725a2a6df77c069f46050899e74996054efabf44bef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/08941938909018267$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/08941938909018267$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,60409,61194,61375</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2488006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hershman, Michael J.</creatorcontrib><creatorcontrib>Trachtenberg, Laura S.</creatorcontrib><creatorcontrib>Pietsch, James D.</creatorcontrib><creatorcontrib>Richard Mooney, T. H.</creatorcontrib><creatorcontrib>Deweese, R. Craig</creatorcontrib><creatorcontrib>Cheadle, William G.</creatorcontrib><title>Evaluation of Copovithane as a Nonspecific Immunomodulator in Surgically Simulated Sepsis</title><title>Journal of investigative surgery</title><addtitle>J Invest Surg</addtitle><description>Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis. The purpose of this study was to compare CPV with muramyl dipeptide (MDP), (in immunomodulator of proven efficacy in simulated surgical infection. Six groups of CBA/J mice were compared; they received intramuscular injections of normal saline (controls), MDP (100 µg), or CPV (100, 200, and 400 mg/kg) 24 h prior to bacterial challenge. The challenge consisted of a Klebsiella-impregnated thigh suture. The first experiment assessed survival after bacterial challenge. The MDP and the CPV groups both had median survival times of 3 days, significantly longer than the control group (1 day, p <.05). In the second experiment, animals were sacrificed at 6, 24, and 48 h following bacterial challenge, and blood and infected muscle were taken for quantitative bacteriology. At 6 h, there was no difference between groups. Both the MDP rind CPV groups had significantly (p <. 05) lower blood bacterial counts than the control group at 24 and 48 h. Both the MDP and CVP groups had significantly lower local bacterial recovery than controls at 48 h (p <. 05), and local bacterial recovery of the MDP group was significantly lower than the control group at 24 h (p <.05). CPV improved survival and reduced local and systemic bacterial recovery compared with controls. Although the effect of CPV was similar to MDP in this model, it consistently was of lower magnitude and had a narrow dose range.</description><subject>Acetylmuramyl-Alanyl-Isoglutamine - therapeutic use</subject><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Animals</subject><subject>Carbamates - therapeutic use</subject><subject>Copovithane</subject><subject>Disease Models, Animal</subject><subject>Equipment Contamination</subject><subject>immunomodulator</subject><subject>infection</subject><subject>Klebsiella Infections - etiology</subject><subject>Klebsiella Infections - immunology</subject><subject>Klebsiella Infections - therapy</subject><subject>Klebsiella pneumoniae - immunology</subject><subject>Mice</subject><subject>Mice, Inbred CBA</subject><subject>muramyl dipeptide</subject><subject>Povidone - therapeutic use</subject><subject>Sepsis - etiology</subject><subject>Sepsis - immunology</subject><subject>Sepsis - therapy</subject><subject>Surgical Wound Infection - etiology</subject><subject>Surgical Wound Infection - immunology</subject><subject>Surgical Wound Infection - therapy</subject><subject>Sutures</subject><issn>0894-1939</issn><issn>1521-0553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtKxDAUDaLo-PgAF0JW7qpJmz6CbmQYdWDQxejCVblNEyeSNjVplfl7U2YQRHR1L_c8uOcgdErJRUIJvyQFZ5QnBSec0CLO8h00oWlMI5KmyS6ajHgUCPwAHXr_RgiJGU_20X7MioKQbIJeZh9gBui1bbFVeGo7-6H7FbQSg8eAH2zrOym00gLPm2ZobWPrwUBvHdYtXg7uVQswZo2XuhnvssZL2Xntj9GeAuPlyXYeoefb2dP0Plo83s2nN4tIxFnRRxWTFIQKcWImVCpkWrE6j1OIIatVnguSccUykoYsXOaM87AzqaBSjFVSJUfofOPbOfs-SN-XjfZCGhMy2MGXOU9zyjIWiHRDFM5676QqO6cbcOuSknKss_xVZ9Ccbc2HqpH1t2LbX8CvN7hulXUNfFpn6rKHtbFOOWiF9qP13_ZXP-QrCaZfCXCyfLODa0Nv_zz3BYlAlpY</recordid><startdate>1989</startdate><enddate>1989</enddate><creator>Hershman, Michael J.</creator><creator>Trachtenberg, Laura S.</creator><creator>Pietsch, James D.</creator><creator>Richard Mooney, T. H.</creator><creator>Deweese, R. Craig</creator><creator>Cheadle, William G.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1989</creationdate><title>Evaluation of Copovithane as a Nonspecific Immunomodulator in Surgically Simulated Sepsis</title><author>Hershman, Michael J. ; Trachtenberg, Laura S. ; Pietsch, James D. ; Richard Mooney, T. H. ; Deweese, R. Craig ; Cheadle, William G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-b4e1acf31024cf5ce5b4d725a2a6df77c069f46050899e74996054efabf44bef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Acetylmuramyl-Alanyl-Isoglutamine - therapeutic use</topic><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Animals</topic><topic>Carbamates - therapeutic use</topic><topic>Copovithane</topic><topic>Disease Models, Animal</topic><topic>Equipment Contamination</topic><topic>immunomodulator</topic><topic>infection</topic><topic>Klebsiella Infections - etiology</topic><topic>Klebsiella Infections - immunology</topic><topic>Klebsiella Infections - therapy</topic><topic>Klebsiella pneumoniae - immunology</topic><topic>Mice</topic><topic>Mice, Inbred CBA</topic><topic>muramyl dipeptide</topic><topic>Povidone - therapeutic use</topic><topic>Sepsis - etiology</topic><topic>Sepsis - immunology</topic><topic>Sepsis - therapy</topic><topic>Surgical Wound Infection - etiology</topic><topic>Surgical Wound Infection - immunology</topic><topic>Surgical Wound Infection - therapy</topic><topic>Sutures</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hershman, Michael J.</creatorcontrib><creatorcontrib>Trachtenberg, Laura S.</creatorcontrib><creatorcontrib>Pietsch, James D.</creatorcontrib><creatorcontrib>Richard Mooney, T. H.</creatorcontrib><creatorcontrib>Deweese, R. Craig</creatorcontrib><creatorcontrib>Cheadle, William G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigative surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hershman, Michael J.</au><au>Trachtenberg, Laura S.</au><au>Pietsch, James D.</au><au>Richard Mooney, T. H.</au><au>Deweese, R. Craig</au><au>Cheadle, William G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Copovithane as a Nonspecific Immunomodulator in Surgically Simulated Sepsis</atitle><jtitle>Journal of investigative surgery</jtitle><addtitle>J Invest Surg</addtitle><date>1989</date><risdate>1989</risdate><volume>2</volume><issue>4</issue><spage>423</spage><epage>429</epage><pages>423-429</pages><issn>0894-1939</issn><eissn>1521-0553</eissn><abstract>Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis. The purpose of this study was to compare CPV with muramyl dipeptide (MDP), (in immunomodulator of proven efficacy in simulated surgical infection. Six groups of CBA/J mice were compared; they received intramuscular injections of normal saline (controls), MDP (100 µg), or CPV (100, 200, and 400 mg/kg) 24 h prior to bacterial challenge. The challenge consisted of a Klebsiella-impregnated thigh suture. The first experiment assessed survival after bacterial challenge. The MDP and the CPV groups both had median survival times of 3 days, significantly longer than the control group (1 day, p <.05). In the second experiment, animals were sacrificed at 6, 24, and 48 h following bacterial challenge, and blood and infected muscle were taken for quantitative bacteriology. At 6 h, there was no difference between groups. Both the MDP rind CPV groups had significantly (p <. 05) lower blood bacterial counts than the control group at 24 and 48 h. Both the MDP and CVP groups had significantly lower local bacterial recovery than controls at 48 h (p <. 05), and local bacterial recovery of the MDP group was significantly lower than the control group at 24 h (p <.05). CPV improved survival and reduced local and systemic bacterial recovery compared with controls. Although the effect of CPV was similar to MDP in this model, it consistently was of lower magnitude and had a narrow dose range.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>2488006</pmid><doi>10.3109/08941938909018267</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0894-1939 |
| ispartof | Journal of investigative surgery, 1989, Vol.2 (4), p.423-429 |
| issn | 0894-1939 1521-0553 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79571464 |
| source | Taylor & Francis:Master (3349 titles); MEDLINE |
| subjects | Acetylmuramyl-Alanyl-Isoglutamine - therapeutic use Adjuvants, Immunologic - therapeutic use Animals Carbamates - therapeutic use Copovithane Disease Models, Animal Equipment Contamination immunomodulator infection Klebsiella Infections - etiology Klebsiella Infections - immunology Klebsiella Infections - therapy Klebsiella pneumoniae - immunology Mice Mice, Inbred CBA muramyl dipeptide Povidone - therapeutic use Sepsis - etiology Sepsis - immunology Sepsis - therapy Surgical Wound Infection - etiology Surgical Wound Infection - immunology Surgical Wound Infection - therapy Sutures |
| title | Evaluation of Copovithane as a Nonspecific Immunomodulator in Surgically Simulated Sepsis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T03%3A09%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Copovithane%20as%20a%20Nonspecific%20Immunomodulator%20in%20Surgically%20Simulated%20Sepsis&rft.jtitle=Journal%20of%20investigative%20surgery&rft.au=Hershman,%20Michael%20J.&rft.date=1989&rft.volume=2&rft.issue=4&rft.spage=423&rft.epage=429&rft.pages=423-429&rft.issn=0894-1939&rft.eissn=1521-0553&rft_id=info:doi/10.3109/08941938909018267&rft_dat=%3Cproquest_pubme%3E79571464%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79571464&rft_id=info:pmid/2488006&rfr_iscdi=true |